Arbutus Biopharma logo

ABUS - Arbutus Biopharma Share Price

$4.05 0.1  2.3%

Last Trade - 22/01/21

Small Cap
Market Cap £251.3m
Enterprise Value £164.9m
Revenue £4.49m
Position in Universe 3766th / 6630
Unlock ABUS Revenue
Relative Strength (%)
1m -3.89%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -55.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
15.0 23.3 1.49 10.7 5.95 6.01 6.54 9.51 -16.7%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ArbutusBiopharma Corp revenues increased 3% to $4.5M. Net lossapplicable to common stockholders decreased 59% to $55.7M.Revenues reflect Royalty increase from $887K to $2M. Lowernet loss reflects Impairment of intangible assets decreasefrom $43.8M (expense) to $0K, Impairment of goodwilldecrease from $22.5M (expense) to $0K, Equity investmentloss decrease of 78% to $2.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ABUS Revenue Unlock ABUS Revenue

Net Income

ABUS Net Income Unlock ABUS Revenue

Normalised EPS

ABUS Normalised EPS Unlock ABUS Revenue

PE Ratio Range

ABUS PE Ratio Range Unlock ABUS Revenue

Dividend Yield Range

ABUS Dividend Yield Range Unlock ABUS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABUS EPS Forecasts Unlock ABUS Revenue
Profile Summary

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 1, 2018
Public Since November 13, 2010
No. of Shareholders: 102
No. of Employees: 80
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 84,909,258
Free Float (0.0%)
Eligible for
ABUS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABUS
Upcoming Events for ABUS
Frequently Asked Questions for Arbutus Biopharma
What is the Arbutus Biopharma share price?

As of 22/01/21, shares in Arbutus Biopharma are trading at $4.05, giving the company a market capitalisation of £251.3m. This share price information is delayed by 15 minutes.

How has the Arbutus Biopharma share price performed this year?

Shares in Arbutus Biopharma are currently trading at $4.05 and the price has moved by 29.81% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Arbutus Biopharma price has moved by 11.02% over the past year.

What are the analyst and broker recommendations for Arbutus Biopharma?

Of the analysts with advisory recommendations for Arbutus Biopharma, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Arbutus Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Arbutus Biopharma next release its financial results?

Arbutus Biopharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Arbutus Biopharma dividend yield?

Arbutus Biopharma does not currently pay a dividend.

Does Arbutus Biopharma pay a dividend?

Arbutus Biopharma does not currently pay a dividend.

When does Arbutus Biopharma next pay dividends?

Arbutus Biopharma does not currently pay a dividend.

How do I buy Arbutus Biopharma shares?

To buy shares in Arbutus Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Arbutus Biopharma?

Shares in Arbutus Biopharma are currently trading at $4.05, giving the company a market capitalisation of £251.3m.

Where are Arbutus Biopharma shares listed? Where are Arbutus Biopharma shares listed?

Here are the trading details for Arbutus Biopharma:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ABUS
What kind of share is Arbutus Biopharma?

Based on an overall assessment of its quality, value and momentum, Arbutus Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Arbutus Biopharma share price forecast 2021?

Shares in Arbutus Biopharma are currently priced at $4.05. At that level they are trading at 72.84% discount to the analyst consensus target price of 0.00.

Analysts covering Arbutus Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -0.98 for the next financial year.

How can I tell whether the Arbutus Biopharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arbutus Biopharma. Over the past six months, the relative strength of its shares against the market has been -31.35%. At the current price of $4.05, shares in Arbutus Biopharma are trading at 41.64% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Arbutus Biopharma PE Ratio?

We were not able to find PE ratio data for Arbutus Biopharma.

Who are the key directors of Arbutus Biopharma?

Arbutus Biopharma's management team is headed by:

Richard Henriques - IND
Keith Manchester - IND
Michael Sofia - CSO
Elizabeth Howard - EVP
Daniel Burgess - IND
David Hastings - CFO
William Collier - PRE
Frank Torti - CHM
James Meyers - IND
Gaston Picchio - OTH
Michael McElhaugh - OTH
Andrew Cheng - IND
Who are the major shareholders of Arbutus Biopharma?

Here are the top five shareholders of Arbutus Biopharma based on the size of their shareholding:

Roivant Sciences Ltd. Corporation
Percentage owned: 18.86% (16.0m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 7.04% (5.98m shares)
Foresite Capital Management, LLC Private Equity
Percentage owned: 3.92% (3.33m shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 3.42% (2.91m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.64% (2.24m shares)
Similar to ABUS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.